© 2026 Arizent. All rights reserved.

ABS

BioPharma Prices $300 Mln Securitization

Published Updated 1 Min Read

INPDL BioPharma announced that it has priced a $300 million securitization transaction intended to monetize certain of its antibody humanization patents and royalties.

Upon closing of the transaction, which is expected to occur on  Nov. 2, BioPharma will sell to QHP Royalty Sub,  a newly-formed wholly-owned subsidiary of BioPharma, certain rights under its non-exclusive license agreements with Genentech, a wholly-owned subsidiary of Roche Holding.

This includes the right to receive 60% of the royalties from sales of Avastin® (Bevacizumab), Herceptin® (Trastuzumab), Lucentis® (Ranibizumab) and Xolair® (Omalizumab) and from sales of future products, if any. QHP will then issue $300 million in aggregate principal amount of its QHP PhaRMA(SM) senior secured notes due 2015 in a non-registered offering pursuant to Rule 144A and Regulation S. The notes will bear an interest rate of 10.25%.  

BioPharma intends to use a sizable portion of the net offering proceeds from the securitization transaction to pay a special cash dividend to stockholders.

The total amount of the special dividend, together with the record and payment dates, will be decided by the company’s board of directors at its upcoming meeting on Nov. 11 and will be announced the following day.   

For reprint and licensing requests for this article, click here.

More From Asset Securitization Report

Second pharmaceutical royalty ABS quietly prices

After months of marketing, the $225 million pharmaceutical patent royalty securitization from Royalty Pharma Finance Trust, just the second ever such transaction, closed last week after having been placed into an undisclosed conduit. Structured and underwritten by Credit Suisse First Boston, structural changes and additional credit enhancement were added to the trade to mitigate the […]

Pharma Royalty deal update

Credit Suisse First Boston is the lead manager on Royalty Pharma’s pending pharmaceutical patent-backed deal, currently in the marketing stages. This transaction, a follow-up to the Zerit-backed BioPharma Royalty Trust I, is said to be backed by a broader pool of patents. WestLB London agented the first transaction (see ASR 3/24).

Next generation BioPharma looms

It was learned last week that a follow-up deal to BioPharma Royalty Trust is in the works and could emerge in the next several weeks. Unlike the first BioPharma, which was tied to the royalty of HIV drug Zerit, the pending deal will tap the cash flow associated with a pool of patents, allowing diversification […]

BioPharma deal to begin rapid-AM

One of the best-known patent royalty securitizations, BioPharma Royalty Trust, will likely enter into early amortization following the third quarter trustee report due at the end of November. Based on projections associated with Bristol-Myers Squibb Co.’s financial statements and reports, Standard & Poor’s expects BioPharma’s $57.15 million A’ rated senior notes to breach covenants for […]

Biotech enters securitization jungle

While only one biotechnology-patent securitization deal has been completed so far, two Boston-based individuals have proposed a plan to make the process of securitizing these assets simpler. Pat Trombly and Ronald Douglas, who each have tax backgrounds from big-five accounting firms, have devised a way to use “check-the-box” tax regulations to ease the process of […]